41
InnoPharmax Inc.
4172.TWO · TWO
$11.10 -1.33% (-$0.15)
1M +0.45%
Market Cap $1.32B
P/E Ratio -
Div. Yield -
ROE 35.05%
Piotroski F-Score Weak
3/9Valuation
32 /100
Expensive P/B 3.15x
P/S 19.12x
EV/FFO N/A
Growth
82 /100
Growing Book val. growth 0.92%
Rev. growth 33.29%
FCF growth N/A
Profitability
0 /100
Weak Op. margin 248.98%
Gross margin 5.08%
FCF margin 195.29%
Quality
2 /100
Poor ROA 39.32%
ROIC 40.70%
Asset turnover 0.15x
Debt
69 /100
Low Int. coverage -448.46x
Debt/Equity 0.03x
Current ratio 3.52x
Stability
11 /100
Unstable EPS volatility 52.55%
Beta 0.02x
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre 4172.TWO
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Weihua Hao
Employees
33
Headquarters
Taipei